| Literature DB >> 26180517 |
Claudia Petrarca1, Emanuela Clemente2, Valentina Amato1, Paola Pedata3, Enrico Sabbioni1, Giovanni Bernardini4, Ivo Iavicoli5, Sara Cortese2, Qiao Niu6, Takemi Otsuki7, Roberto Paganelli8, Mario Di Gioacchino8.
Abstract
Almost all people in developed countries are exposed to metal nanoparticles (MeNPs) that are used in a large number of applications including medical (for diagnostic and therapeutic purposes). Once inside the body, absorbed by inhalation, contact, ingestion and injection, MeNPs can translocate to tissues and, as any foreign substance, are likely to encounter the innate immunity system that represent a non-specific first line of defense against potential threats to the host. In this review, we will discuss the possible effects of MeNPs on various components of the innate immunity (both specific cells and barriers). Most important is that there are no reports of immune diseases induced by MeNPs exposure: we are operating in a safe area. However, in vitro assays show that MeNPs have some effects on innate immunity, the main being toxicity (both cyto- and genotoxicity) and interference with the activity of various cells through modification of membrane receptors, gene expression and cytokine production. Such effects can have both negative and positive relevant impacts on humans. On the one hand, people exposed to high levels of MeNPs, as workers of industries producing or applying MeNPs, should be monitored for possible health effects. On the other hand, understanding the modality of the effects on immune responses is essential to develop medical applications for MeNPs. Indeed, those MeNPs that are able to stimulate immune cells could be used to develop of new vaccines, promote immunity against tumors and suppress autoimmunity.Entities:
Keywords: Adjuvant; Barriers; Cell receptors; Cytokines; Immunostimulation; Immunotoxicity
Year: 2015 PMID: 26180517 PMCID: PMC4503298 DOI: 10.1186/s12948-015-0020-1
Source DB: PubMed Journal: Clin Mol Allergy ISSN: 1476-7961
Main interactions of metal nanoparticles with receptors of the immune cells
| NP | Cells | Effect | Dose/Diameter | Ref |
|---|---|---|---|---|
| CoNP | Monocyte/Macrophages | -Activation of the innate immune response | [ | |
| -Release of inflammatory cytokines through TLR-4 | ||||
| TiO2NP ZnONP | Human lymphocytes | -No alterations of MDDC phenotype | 10 μg/mL | [ |
| ZnONP | Human lymphocytes | -Down regulation of CD16 on NK-cells | subtoxic | [ |
| AuNP | Macrophages | -Reduction of macrophage response against pathogens | 4-45 nm | [ |
| -Accumulation of NPs in the lysosomes | ||||
| -Inhibition of TRL9 function | ||||
| -Inhibition of TNF-α production |
Main cytotoxic effects of metal nanoparticles on cells of the immune system
| NPs | Cells | Effects | Ref |
|---|---|---|---|
| CoNPs ZnONPs CeO2NPs TiO2NPs | Mononyte/Macrophages | Necrosis (dependent on dose, size, concentration, structure | [ |
| AgNP ZiONP | Monocyte/Macrophages | -IL-8 and IL-1β production (size-dependent) | [ |
| -Oxidative stress | |||
| -Inflammasome induction | |||
| CoNPs | Human PBMCs | -Increase of TNF-α, IFN-γ | [ |
| -Inhibition of IL-2, IL-10 | |||
| CuONP | Neutrophils | -Neutrophil recruitment and activation | [ |
| -Increase of IL-6, IL-12, GM-CSF, KC, MCP-1, MIP-α, TNF-α | |||
| CuONPs | Neutrophils | -Reduced bacterial killing | [ |
| Fe2O3NPs | Lung lymph node cells | -Increased cytokine production | [ |
| ZnONPs | Monocyte/Macrophages | -Toxicity (dose-dependent) | [ |
| -Cell death (ion relese-dependent) | |||
| CoNP | Human PBMC | -Autophagy | [ |
| PdNPs | Human PBMC | -Autophagy | [ |
| -Cell cycle (prolongation of G1-phase) | |||
| -Increase of IL-8 | |||
| Coated NPs | Monocyte-derived macrophages | -Variable cytotoxicity | [ |
Immunostimulating effects of metal nanoparticles on cells of the immune system
| NPs | Cells | Effects | Ref |
|---|---|---|---|
| AgNPs | Human PBMCs | Size dependent IL-1β production (inverse correlation) | [ |
| TiO2NPs AgNPs ZnONPs | Lung macrophages, dendritic cells, basophils, neutrophils and eosinophils | Increase of inflammatory and Th cell activating cytokines (IL-2, IL-4, IL-6, CINC-1, IL-10, TNF-α) | [ |
| Fe2O3 NiNP CoNPs PdNPs | Human peripheral monocytes | Increase of Th1 cytokines | [ |
Immune adjuvant properties of metal nanoparticles
| NPs | Cells | Effects | Ref |
|---|---|---|---|
| AgNPs | Lung | -Reduction of IL-4, IL-5, IL-13 | [ |
| -Reduction of NF-kB | |||
| -Reduction of eosinophilic inflammation (OVA-induced ) | |||
| Fullerenes | Mast cells | -Inhibition of IgE dependent mediator release | [ |
| -Reduction of phosphorylation Syk | |||
| -Inhibition of allergen-induced ROS | |||
| AuNPs AgNPs | Mast cells | -Inhibition of degranulation and serotonine secretion | [ |
| AgNPs | Rat model of spinal cord injury | -Higher anti-NgR antibody | [ |
| AlNPs | Dendritic cells | -Increased MHC and CD86, Cd80 and CD40 (> than Al ions) | [ |
| Fe2O3NPs | Dendritic cells | -Th1 immune activation | [ |
Nanoparticle interaction with cell barriers of the immune system
| NPs | Cells | Effects | Ref |
|---|---|---|---|
| AgNPS TiO2NPs ZnONPs MnONPs CeO2NPs | Human lung epithelium | -ROS production | [ |
| -DNA damage | |||
| -Apoptosis | |||
| Fe2O3NPs | Human bronchial epithelium | -Genotoxicity | [ |
| NiNPs | Lung | -Reduction of cell viability | [ |
| -Apoptosis | |||
| -Necrosis | |||
| -Increase of ROS, IL-6 and IL-8 (MAPK-dependent, NF-kB-mediated) | |||
| ZnNPs | Human bronchial epithelial cells | -Increased of IL-8 (dose-dependent) | [ |
| -Activation of NFκB and C/EBPβ | |||
| MeNPs ZnONPs | Gut epithelium | -Generation of ROS | [ |
| -Release of IL-8 | |||
| -Cytotoxicity (size dependent) | |||
| AgNPs TiO2NPs | Intestinal epithelium | -Cell death (SW480 cells) | [ |
| -IL-8 production | |||
| -ROS generation | |||
| AgNPs | Mice intestinal epithelium | -Damage of microvilli and intestinal glands | [ |
| -Malabsorption syndrome | |||
| TiO2NPs | Caco-2 | -Cross monolayers without disruption of junctional complexes and without causing cytotoxicity | [ |
| TiO2NPs AgNPs | Bronchial and intestinal eptithelium | -Abnormal mucus production | [ |